Expression and Purification of a Mammalian Protein: Cytosolic Domain of IRE1 α from Insect Sf21 Cells

Amrita Oak¹, Grace Jansen¹ and Christina Chan^{1,2, *}

¹ Dept. of Chemical Engineering and Materials Science, Michigan State University;

² Dept. of Biochemistry and Molecular Biology, Michigan State University

* Correspondence: krischan@egr.msu.edu;

Abstract: Eukaryotic proteins can be expressed in different heterologous systems. However, mammalian proteins in general have specific post-translational processing requirements that may not be fulfilled by a regular bacterial expression system. In this study, we use an insect cell system to express a mammalian protein of interest. *Spodoptera frugiperda* (Sf21) cells were used in conjunction with a baculoviral expression system to produce the cytosolic domain (CD) of IRE1, an endoplasmic reticulum (ER) stress sensor protein. Inositol Requiring Enzyme 1 (IRE1) is a dual function kinase and endoribonuclease protein that cleaves X-box binding protein (XBP1) mRNA. We used the pFastBac plasmid to insert the coding sequence into a recombinant bacmid shuttle vector which was then used to infect Sf21 cells. The expressed protein was then purified with an MBPTrap column to obtain >85% pure protein.

Keywords: Sf21 cells; baculoviral expression; IRE1; pFastBac; MBP-tagged protein purification

1. Introduction

Heterologous expression of proteins is defined as the expression of proteins in an organism that does not naturally express the protein. The different systems in use for such purposes can be broadly classified as bacterial, yeast, insect and mammalian systems. Cells in culture can be manipulated to express the protein of interest in transient or stable mode. Some factors that need to be considered while choosing the expression system are the required yield of the protein, post-translational modifications, functionality, and speed of expression.

Proteins of prokaryotic origin are best expressed in bacterial systems. *E. coli* can express and adequately process prokaryotic proteins and is the go-to system for cheap, scalable and high yield expression. If the expression of eukaryotic proteins is required, additional factors need to be taken into consideration. The most important factor would arguably be the level of post-translational modifications (PTM) required for a functional form of the protein. Proteins requiring extensive PTMs will not be processed correctly in bacterial systems and will most likely aggregate in inclusion bodies[1]–[3]. Adding a fusion protein tag to the protein of interest may sometimes help to resolubilize the proteins. However, in the interest of saving time and effort, it is advisable to switch to higher eukaryotic systems such as insect or mammalian cells. Another advantage to eukaryotic systems is the presence of extensive protein folding machinery that is vital for the function of the protein [4].

Table 1 compares the different heterologous protein expression systems with respect to the type of protein, post-translational modifications and ease of large-scale production [5]–[10].

Table 1: Characteristics of heterologous protein expression in bacterial, yeast, insect and mammalian cell systems ranked according to desirability

	Bacterial	Yeast	Insect	Mammalian
Type of protein				
Prokaryotic	Y	Y	Y	Y
Eukaryotic	Y	Y	Y	Y
Secreted	Y	Y	Y	Y
Post-translation modifications				
Phosphorylation	Y	Y	Y	Y
Glycosylation	N	Y	Y	Y
Acetylation	N	Y	Y	Y
Acylation	N	Y	Y	Y
Refolding required?	Y	Y	N	N
Production				
Cell growth	Rapid (30 mins)	Rapid (1.5 hrs)	Moderate (18 hrs)	Slow (24hrs)
Yield	High	High	Moderate	Low
Time to expression	Rapid	Moderate	Moderate	High
Cost	Low	Expensive	Expensive	Very expensive
Ease of scale-up	Easy	Easy	Difficult	Very difficult

Bacterial systems have desirable characteristics for large scale production but are not able to process and correctly fold proteins requiring extensive PTMs [11]. Depending on the application of the protein, Chinese hamster ovary (CHO) or Human embryonic kidney (HEK 293) cells are typically the system of choice for eukaryotic proteins [12]. This is true, especially for therapeutic proteins or antibodies. However, the yield is very low compared to insect or bacterial cells – typically on the order of 100mg/L of expressed protein [13]. The level of protein expression is higher in insect cells up to 100mg/ L [14], [15].

Insect cells and mammalian systems have a wide range of post-translational modifications. An excellent tool to determine all possible post-translational modifications of a protein of interest is dbPTM (<http://dbptm.mbc.nctu.edu.tw/>). Insect and mammalian systems are both capable of all PTMs with one exception. Insect cells and mammalian cells have similar phosphorylation and O-linked glycosylation patterns. They can authentically process phosphorylation modifications, partly due to the presence of phosphatases. However, in terms of N-glycosylation, proteins in insect cells are high-mannosylated while mammalian cells have a complex glycosylation pattern [4], [12]. **Figure 1** depicts the difference in N-linked glycosylation patterns in insect cells vs. mammalian cells. Regular insect Sf9 and Sf21 cells will have a high mannose pattern of glycosylation but mimic Sf9 (available from ThermoFisher) cells are engineered to make complex N-glycans with terminal sialic acid. Varied and complex sugars such as N-acetylneuraminic acid, galactose, fucose, mannose are added in mammalian cells in a branched configuration as opposed to the addition of only mannose residues in insect cells.

Figure 1: N-linked glycosylation patterns for insect cells and mammalian cells

In this study, we developed a protocol to express the Inositol Requiring Enzyme-1 α (IRE1 α) protein, an ER stress sensor. IRE1 is a type I transmembrane protein primarily composed of three domains, the luminal domain, a transmembrane domain and cytosolic domain (CD)[16].

IRE1 α is a bifunctional protein with kinase and endoribonuclease activity on the CD. We have developed a protocol to produce IRE1 α -CD (547-977 aa) in insect Sf21 cells using baculovirus expression. IRE1 α has been expressed in *E. coli* cells in our lab (unpublished data) as well as by other groups[17], [18]. However, IRE1 α expressed in *E. coli* and yeast systems is in a hyperphosphorylated state[18], [19]. All the purification methods used thus far for purifying this protein have used the 6X His tag. The cell line used was Sf9 [18], [22]. However, there are no detailed methods or protocol papers published for this procedure, that is, using the Sf9 cells and 6X His tag method.

Post-translational modifications for IRE1 were predicted using algorithms developed by the Center for Biological Sequence Analysis, Technical University of Denmark (<http://www.cbs.dtu.dk/> [1]). The predicted N-glycosylation, O-glycosylation, C-mannosylation and glycation sites are scored for the likelihood of modification (Table 2). The scores that cross the threshold (which is set by the algorithm at 0.5) are denoted as “positive” hits.

Table 2: Predictions for O-glycosylation, C-mannosylation, N-glycosylation and glycation sites on CD-IRE1.

O-glycosylation				C-mannosylation			
start	end	score	comment	start	end	score	comment
2	2	0.792	#POSITIVE	191	191	0.18	.
3	3	0.796	#POSITIVE	287	287	0.271	.
5	5	0.791	#POSITIVE				
15	15	0.189					
16	16	0.506	#POSITIVE				
24	24	0.111					
38	38	0.015					
61	61	0.043					
73	73	0.040					
85	85	0.006					
102	102	0.018					
121	121	0.110					
126	126	0.102					
127	127	0.213					
128	128	0.181					
135	135	0.052					
151	151	0.107					
164	164	0.034					
178	178	0.107					
180	180	0.741	#POSITIVE				
183	183	0.643	#POSITIVE				
188	188	0.111					
198	198	0.148					
206	206	0.026					
208	208	0.047					
213	213	0.013					
223	223	0.070					
226	226	0.040					
232	232	0.064					
245	245	0.252					
276	276	0.510	#POSITIVE				
288	288	0.454					
300	300	0.102					
300	300	0.102					

Glycation			
start	end	score	comment
22	22	-0.943	.
28	28	-0.707	.
53	53	0.801	YES
87	87	-0.875	.
110	110	0.832	YES
144	144	-0.529	.
158	158	0.699	YES
160	160	0.863	YES
170	170	-0.773	.
171	171	0.83	YES
202	202	-0.95	.
231	231	-0.962	.
253	253	-0.799	.
265	265	0.806	YES
273	273	-0.94	.
282	282	-0.878	.
291	291	-0.83	.

N-glycosylation			
start	end	score	comment
204	204	0.5427	+

2. Experimental Design

2.1 Materials

All the materials are listed separated by each sub-section of the procedure.

Cloning of IRE1 α -CD into pFastBac plasmid

- i. pFastBac His6 MBP N10 TEV LIC cloning vector (4C) (Addgene plasmid #30116)
- ii. SspI-HF (New England Biolabs, cat # R3132S)
- iii. CutSmart buffer (New England Biolabs cat# B7204S)
- iv. QIAquick PCR Purification Kit (Qiagen, cat# 28104)
- v. Deoxynucleotide (dNTP) set includes dGTP, dCTP (New England Biolabs, cat # N0446S)
- vi. Bovine Serum Albumin (BSA), Molecular Grade (New England Biolabs, cat# B9000S)
- vii. T4 DNA Polymerase (New England Biolabs, cat# M0203S)
- viii. Q5 High Fidelity 2X Master Mix (New England Biolabs, cat# M0492S)
- ix. OneShot Top10 chemically competent *E. coli* DH5 α (ThermoFisher, cat# C404003)
- x. Luria Broth (Sigma-Aldrich, cat# L3397)
- xi. Luria Agar (Sigma-Aldrich, cat# L3272)
- xii. LB agar plates containing ampicillin (Sigma-Aldrich, cat # L5667-10EA)

Preparation of recombinant bacmid

- xiii. MAX Efficiency *E. coli* DH10Bac competent cells (ThermoFisher cat# 10361012)

xiv. Antibiotics and their stock solutions are listed in **Table 3**. Aliquot and store at -20°C.

Table 3: Antibiotic concentrations and stock solutions

Component	Dissolve in	Company (Cat. No)	Stock conc.	Special considerations
Kanamycin	Water	Sigma (60615)	50 mg/mL	
Tetracycline	Ethanol	Sigma (87128)	10 mg/mL	Light sensitive
Gentamicin	Water	Sigma (G1914)	7 mg/mL	
X-gal**	Dimethyl formamide	Sigma (XGAL-RO)	20 mg/mL	Light sensitive, DO NOT filter sterilize, Make solution in a glass vial or polypropylene tube
IPTG	Water	Sigma (I6758)	200 mg/mL	Filter sterilize

** There are other options for X-gal such as *Bluo-gal* (ThermoFisher, cat # 15519028). It is more expensive but more sensitive and turns a deeper, more obvious blue that aids in colony identification**

xv. S.O.C medium (ThermoFisher cat# 15544034)

xvi. PureLink HiPure Plasmid Miniprep Kit (Invitrogen, cat# K210002)

Transfection of recombinant bacmid into Sf21 cells

i. Sf-900-III serum-free media (ThermoFisher, cat# 12658019)

ii. Cellfectin II reagent (ThermoFisher, cat# 10362100)

iii. Gelcode Blue Stain Reagent (ThermoFisher, cat# 24590)

iv. IRE1α (14C10) Rabbit mAb (Cell Signaling Tech, cat# 3294)

Protein purification using MBPTrap column

v. Xtractor cell lysis buffer (Takara, cat# 635671)

vi. cOmplete, Mini, EDTA-free protease inhibitor cocktail (Sigma, cat# 11836170001)

vii. MBPTrap HP column (GE, cat# 28-9187-78)

viii. D-(+)- Maltose monohydrate (Sigma, cat# 63418-25G)

ix. Tris-Cl (Sigma, cat # 10812846001)

x. NaCl (Sigma, cat # S3014)

xi. Dithiothreitol (DTT) (Sigma, cat# DTT-RO)

xii. EDTA (Sigma, cat # 324504)

xiii. Phosphate buffered saline (PBS) (Sigma, cat# P7059-1L)

xiv. Binding buffer for MBPTrap HP column: 20 mM Tris-HCl, 200 mM NaCl, 1 mM DTT, 1 mM EDTA, pH 7.4

xv. Elution Buffer for MBPTrap HP column: Binding buffer + 10mM maltose

xvi. Regeneration buffer: 0.5M NaOH

3. Procedure

Figure 2 depicts a flowchart of the steps involved in the expression and purification of IRE1α-CD in Sf21 cells using baculoviral vectors. The procedure is divided into 5 subunits. The time required for each subunit is indicated in brackets in the left column (**Figure 2**).

Figure 2: Flowchart for all the steps involved in the expression and purification of proteins from Sf21 cells

3.1 Cloning of IRE1α-CD into pFastBac plasmid

Note:

pFastBac His6 MBP N10 TEV LIC cloning vector (4C) was a gift from Scott Gradia (Addgene plasmid #30116; <http://n2t.net/addgene:30116>; RRID: Addgene_30116). Another version of this plasmid (5C) is available so that two proteins can be expressed simultaneously. The sequence for IRE1α-CD was obtained from NCBI (Gene id: 2081). Primers were designed to clone the CD fragment from 547 aa-977 aa from a pCDNA-hIRE1 plasmid containing a full-length IRE1 coding sequence.

Table 4: PCR primers for insertion of IRE1-CD (547aa-977aa) into pFastBac plasmid

CD_IRE1_forward	5'- <u>TACTTCCAATCCAATGCAGGCAGCAGCCCCTCCCTGGAAC</u> -3'
CD_IRE1_reverse	5'- <u>TTATCCACTTCCAATGTTATTAGAGGGCGTCTGGAGTCAC</u> -3'

Table 4 shows the primers designed for the insertion of IRE1 α -CD into the empty pFastBac plasmid. The underlined tag on each primer is to facilitate ligation independent cloning (LIC) and is specific to the pFastBac backbone. The rest of the primer is specific to the insert coding sequence (CDS). The LIC technique makes use of the endonuclease activity of T4 DNA polymerase to generate sticky overhangs for ligation between the vector plasmid and insert DNA. This technique avoids the use of ligases.

Protocol:

Preparing the vector pFastBac plasmid

- i. Linearize the plasmid with SspI-HF (NEB) (**Table 5**). The high-fidelity (HF) versions of restriction enzymes are faster and more efficient. Incubate at 37°C for 15 mins – 2 hrs to completely digest all the plasmid DNA. Heat inactivation is performed for 20 mins at 65°C.

Table 5: Restriction digestion with SspI-HF

Component	Amount	Volume (μ L)
pFastBac plasmid DNA (250ng/ μ L)	1 μ g	4
10X CutSmart buffer	Final concentration 1X	5
SspI-HF	10 units	1
Water	Make up to 50 μ L	40

- ii. Use a PCR purification kit (QIAquick) to purify the large linearized fragment of plasmid DNA.
- iii. To create pFastBac vector overhangs, mix the following components in PCR tubes, the order of addition is as listed (T4 DNA polymerase is added last) (**Table 6**). Incubate at 12°C for 30 minutes followed by heat inactivation at 75°C for 20 minutes.

Table 6: Mix to create pFastBac vector overhangs

Reagent	Final conc.	Volume (μ L)
10x NEB 2.1	1x	4
Eluted linearized pFastBac DNA	10-50 ng/ μ L	20-30
dGTP (100mM)	2.5 mM	1
DTT (100mM)	5 mM	2
BSA (10 ug/ μ L)	0.25 μ g/ μ L	0.6
T4 DNA polymerase	0.075 units/ μ L	1
Sterile dH ₂ O to 40 μ L		

Preparing the insert IRE1 α -CD

- iv. Set up a PCR to amplify the IRE1 α -CD insert using the primers in **Table 4** as outlined in **Table 7**. Confirm amplification by running the PCR product on a 1.5% agarose gel.

Table 7: PCR mix for preparing IRE1 α -CD insert

Component	Volume (μ L)
Q5 2X Master Mix	25
CD_IRE1_forward primer (10 μ M)	2
CD_IRE1_reverse primer (10 μ M)	2
pCDNA-hIRE1 (50 ng/ μ L)	1
Nuclease free water (make up to 50 μ L)	20

The PCR program should be run for 98°C 1 min, followed by 35 cycles of 98°C for 30 sec, 61°C for 10 sec, 72°C for 90 sec, and a final extension of 72°C for 5 mins.

- v. Create the insert overhangs in a way similar to the vector overhangs in the presence of dCTP (instead of dGTP).
- vi. After heat inactivation, mix both vector and insert together (1:3 ratio). The total volume of the combined vector and insert should be between 5-10 μ L. Incubate for 5 mins at room temperature and then add 1 μ L of 25 mM EDTA followed by another incubation for 5 mins.
- vii. Transform 2 μ L of this mixture into competent OneShot Top10 *E. coli* DH5 α (100 μ L), spread onto LB agar plates containing 100 μ g/mL ampicillin and incubated at 37°C for 16-24 hrs.
- viii. Select individual colonies (5-10) and prep the plasmid DNA. Confirm the insertion of IRE1 α -CD by DNA sequencing using primers specific to the IRE1 α -CD sequence (seq for- 5'- aagcagctccagttcttccaggac-3')

3.2 Preparation of recombinant bacmid

Note:

Once the insert has been cloned into the pFastBac empty plasmid, it needs to be transformed into *E. coli* DH10Bac cells to form the recombinant bacmid. *E. coli* DH10Bac competent cells are sold by ThermoFisher. The genotype is F-mcrA Δ (mrr-hsdRMS-mcrBC) Φ 80lacZ Δ M15 Δ lac X74 recA1 endA1 araD139 Δ (ara, leu)7697 galU galK λ - rps L nupG /pMON14272 / pMON7124. DH10Bac cells have a baculovirus shuttle vector and a helper plasmid. This machinery is required for the generation of recombinant bacmid after transformation of pFastBac-IRE1 α -CD into the cells. The baculovirus shuttle vector (bMON14272) also encodes kanamycin resistance, and the helper plasmid (pMON7142) has tetracycline resistance. The presence of the Φ 80lacZ Δ M15 Δ lac marker enables the use of blue/white colony screening to determine integration of the insert into the bacmid. pFastBac has the Tn7 element which includes the polyhedrin promoter, the gene of interest and gentamicin resistance.

It is also possible to use regular *E. coli* DH10Bac cells and make them chemically competent (see **Supplemental file**).

Protocol:

- i. Dissolve LB agar powder in water and autoclave at 121°C for 15 mins.
- ii. Let it cool to 55°C (there should be no lumps of agar).
- iii. Add all the antibiotics and chemicals in the working concentrations listed in **Table 8**.

Table 8: Working concentrations of antibiotics

Component	Stock conc.	Working conc.	Dilution
Kanamycin	50 mg/mL	50 μ g/mL	1:1000
Tetracycline	10 mg/mL	10 μ g/mL	1:1000

Gentamicin	7 mg/mL	7 µg/mL	1:1000
X-gal	20 mg/mL	200 µg/mL	1:100
IPTG	200 mg/mL	40 µg/mL	1:200

233

234 iv. Let harden, store at 4°C in the dark.

235 v. Thaw a vial of competent *E. coli* DH10Bac cells on ice in a 15 mL round bottom
236 sterile polypropylene tube.

237 **Do not use 1.7 mL or 2 mL microcentrifuge tube**

238 vi. Add 100ng pFastBac-IRE1-CD plasmid DNA to the vial.

239 vii. Incubate on ice for **30 mins**.

240 viii. Heat shock for **45 s** at **42°C**.

241 ix. Transfer tubes back on ice and chill for 5 mins.

242 x. Add **900 µL** SOC medium.

243 xi. Incubate tubes in a shaking incubator, 37°C at 200 rpm for at least **4 hrs**.

244 **This 4 hr long outgrowth step is necessary to allow the bacteria to generate the
245 antibiotic resistance proteins encoded on the plasmid backbone**

246 xii. Make three 10-fold serial dilutions of 800 µL cells. Plate 100uL of each dilution onto
247 LB plates with kanamycin, tetracycline, gentamicin, X-gal and IPTG.

248 xiii. Incubate plates at 37°C for **48 hrs** to allow enough time for colony formation and color
249 development. Pick white colonies.

250 **Do not pick colonies before 48 hrs because it may be difficult to distinguish between
251 white and blue colonies**

252 **Pick colonies that are large and well isolated. Avoid picking colonies that are gray or
253 darker in the center as they may contain a mixture of empty bacmid and recombinant
254 bacmid**

255 xiv. Replate selected colonies for an additional round of selection on fresh LB agar plates
256 overnight at 37°C.

257 xv. Once the white phenotype is confirmed, inoculate in LB media with kanamycin,
258 gentamicin, and tetracycline and grow overnight.

259 xvi. Isolate recombinant bacmid DNA using Purelink HiPure Plasmid Kit by Invitrogen with
260 a modified protocol (see **Supplemental file**).

261

262 3.3 Transfection of recombinant bacmid into Sf21 cells

263 *Note:*

264 Sf21 cells are suspension cells grown at 28°C, without the need for CO₂ incubators. They
265 are grown in Sf-900 III media. The media can be supplemented, if needed, with serum but
266 bovine serum should not be used (fetal bovine serum (FBS) is preferred). The serum needs
267 to be inactivated to inactivate complement fragments that can inactivate baculoviruses.
268 Transfection reagents can be lipid based (e.g. cellfectin, fugene). Calcium chloride can be
269 used for baculovirus transfection, but it has less efficiency than lipid-based reagents.

270

271 **Protocol:**

272 *Transfection of bacmid into Sf21 cells*

273 i. A day before transfection, passage Sf21 cells so that they are at a density of 3 x 10⁵
274 cells/mL.

275 **Actively dividing cells have a higher transfection efficiency and produce more protein**

276 ii. Plate cells at a concentration of 8 x 10⁵ cells/well of a 24-well plate.

277 iii. Allow the cells to attach for 1 hr and replace media with fresh media (without FBS).

278 iv. Use 2 µg of bacmid DNA per well. Dilute in 75 µL of Sf 900-III media. Incubate for
279 15 mins.

- v. Use 8 μ L of cellfectin II in 75 μ L media. Incubate for 15 mins.
Make sure the cellfectin II is mixed thoroughly before use, but do not vortex the tube
- vi. Mix together the two tubes and incubate for 15-30 mins.
- vii. Add mixture dropwise to the wells of the 24-well plate.
- viii. 24 hrs later, replace transfection media with fresh SF-900 III media containing 10% FBS.
Serum proteins in FBS act as substrates for proteases
- ix. Check for signs of infection (SIF) after 24 hrs up to 96 hrs.
SIF may not be obvious in P0 infection so continue infection for 5 days and collect the supernatant and re-infect for 5 more days to amplify the viral stock
- x. After changing media, collect supernatant after every 24 hrs for 24, 48, 72 and 96 hrs. This supernatant is the P0 viral stock. Store at 4°C in the dark.
- xi. Use the P0 viral stock to infect newly plated Sf21 cells to generate P1 stock. Add 150 μ L of P0 stock dropwise on top of the cells (plated in a 6-well plate), gently swirl a few times and incubate the plate at 28°C.
- xii. Look for SIF in 24 hours post infection time. After 5 days, collect only P1 viruses with SIF and store viral stocks in the dark at 4°C.
- xiii. In a similar fashion, collect P2, P3 and P4 stocks for increased baculoviral titer with an increasing number of cells infected (6-well plate $\rightarrow$ 150 cm dish $\rightarrow$ T25 flask). Store all at 4°C protected from light.

Scale-up of heterologous protein expression

- i. Seed Sf21 cells in a T75 (vented) flask as described in the transfection procedure. Make sure they are actively dividing cells in the log phase of growth.
- ii. Add 150 μ L of the collected P1 stock.
- iii. Incubate at 27°C for 5 days or until 30-40 % of the cells have lysed.
- iv. Collect cells as well as supernatant. **This will be the P2 viral stock.**
- v. Use P2 viral stock to infect spinner flasks with Sf21 cells.
- vi. If no signs of infection are observed, infect Sf21 cells with the P2 stock of baculoviruses and collect the P3 viral stock (see **Figure 5** for SIF). We concentrated the baculovirus viral supernatants with successive passages (P1,P2,P3) and used the passage that gave us visible signs of infection at 24 hrs with expression of protein. The viral titer (expressed as plaque-forming units/mL or pfu/mL) can also be determined with a plaque assay. Briefly, cells in a tissue culture dish are infected and overlaid with agarose. After the cells are grown for about 10 days, the plaques can be counted to determine the pfu/mL concentration.

3.4 Purification of MBP fusion protein

Note:

For this protocol, use Sf21 cells infected with P3 stock of baculovirus for 96 hrs. The cell pellet is collected and lysed with Xtractor buffer, and an MBPTrap column is used to extract MBP-tagged IRE1 α -CD. The MBP tag can be cleaved from the protein by incubating with 1 unit of AcTEV protease (ThermoFisher, cat# 12575015) for 1 hr at 30°C for each 3 μ g protein.

Protocol:

- i. Prepare Xtractor buffer with protease inhibitor of choice. In this purification protocol, we used cOmplete EDTA free protease inhibitor cocktail.
- ii. Pellet Sf21 cells at 100 x g for 15 mins, remove supernatant media and wash pellet once with phosphate buffered saline (PBS). Add 5 mL Xtractor buffer to 1 g cell pellet.

- iii. Mix vigorously by vortexing and rock at room temperature for 15-30 mins. Make sure that cell lysis is complete by observing under the microscope.
- iv. Centrifuge at 16,000 g for 20-30 mins to pellet the cell debris.
- v. Take the clarified supernatant and filter through a 0.22 μ m filter immediately before loading onto the MBPTrap HP column.
- vi. Prior to loading the clarified lysate, equilibrate the MBPTrap HP column with 7 column volumes (CV) of binding buffer at a flow rate of 1 mL/min
- vii. Load clarified lysate onto the column. The binding capacity of the 1 mL MBPTrap HP column is protein dependent but can bind approximately to 5 mg-7 mg of MBP-tagged protein. The flow rate should be decreased to 0.5 mL/min.
- viii. Wash with 10 CV of binding buffer at a flow rate of 1 mL/min. If real-time A280 readings are possible, wash until no discernible absorbance at 280 nm is observed.
- ix. Add 5 CV of elution buffer at a reduced flow rate of 0.5 mL/min, and assay elute fractions to determine fractions with the highest concentration of the protein of interest with a Bradford or BCA assay.
- x. Regenerate the column with 3 CV distilled water followed by 3 CV of 0.5 M NaOH. Wash away the NaOH with 5 CV distilled water. The column is now ready to be used again.

4. Expected Results

The pFastBac- IRE1 α -CD plasmid features are shown in **Figure 3** [20]. IRE1 α -CD is fused to the C-terminus of an MBP protein under the polyhedrin promoter. A 6X His tag is also present at the N-terminal of the MBP protein. The MBP protein and IRE1 α -CD coding sequences are separated by a Tobacco Etch Virus (TEV) protease site. The plasmid has an ampicillin (amp) and gentamicin (gent) selection marker for selection during the preparation of recombinant bacmid. The pFastBac backbone has a Tn7att transposition element that guides the insertion of the coding sequence into the bacmid. After transformation into *E. coli* DH10Bac, colonies were grown for 48 hrs. Colonies show up within 24 hrs but take an additional day to develop a blue color. Large white colonies were selected and re-streaked onto a Tet-Kan-Gent-IPTG-X-gal plate.

Figure 3: Plasmid map for pFastBac-IRE1 α -CD

After this additional round of selection, a colony PCR was performed to make sure that IRE1 α -CD was incorporated into the recombinant bacmid (**Figure 4**). Primers specific to an internal region in IRE1 α -CD were used. As expected, a band was seen in all of the white colonies picked, indicating that the gene of interest was inserted in the bacmid. Bacmids were prepped and sent for DNA sequencing. Once the IRE1 α -CD sequence was confirmed, glycerol stocks were made for future use (see **Supplemental file**).

Figure 4: Colony PCR of white *E. coli* transformant colonies

The recombinant bacmid was extracted from *E. coli* DH10Bac cells and precipitated with 100% isopropanol to obtain pure bacmid samples. Sf21 cells were transfected and monitored for signs of infection for 5 days and multiple passages of viral titer. **Figure 5** shows the Sf21 cells changing on infection with P3 baculoviruses. The cells become larger in size, and the nuclei appear to occupy more of the cell. The Sf21 cells show more granularity as the infection progresses.

Figure 5: Signs of infection in untransfected Sf21 cells (left) and P3 treated Sf21 cells (right) for 24 hrs. Scale bar = 45μm

We checked the expression of IRE1 α -CD after transfection by collecting cell lysate after P0 and P1 infections. **Figure 6** shows a GelCode Blue-stained SDS-PAGE (8%) of cell lysates after transfection and infection with baculoviruses to express IRE1 α -CD. As evident in the figure, the IRE1 α -CD protein is produced along with other contaminating insect cell proteins, also stained by GelCode Blue and therefore needs to be purified for downstream assays. The proportion of IRE1 α -CD protein expressed in P1 infected cells was more than P0 infected cells, reflecting the higher concentration of baculoviral titer. The baculovirus stock was amplified to P3 to obtain high protein expressing infected Sf21 cells.

The P3 viral supernatant was collected, filtered with a 0.22 μ m filter and stored at 4°C in the dark for subsequent infection. Sf21 cells were passaged the day before infection so that they were in log phase at a density of 3×10^5 cells/mL. 150 μ L of P3 supernatant was added for each mL of Sf21 cells. The time required for the expression of a protein depends on each protein of interest expressed.

Figure 6: Expression of MBP- IRE1 α -CD protein prior to purification. (Left) SDS-PAGE of total protein lysate for untransfected Sf21 cells, P0 and P1 infected clones 1 and 15. The 100 kDa band is marked and the putative 6X His- MBP- IRE1 α -CD protein band is prominent in P1 infections. (Right) Western blot using an anti-IRE1 antibody

Figure 7 shows the western blot for the different time points throughout protein expression to determine the optimum time point for harvesting the cells. For IRE1 α -CD, in P0 infected cells, maximum expression was observed at 96 hrs. Upon increasing infection titer by using P2 stocks, the overall level of protein expression increased. The optimal time point for harvesting was still after 96hrs of infection.

Figure 7: Expression of IRE1-CD protein. Western blot showing the time course of protein expression in P0 (left) and P2 (right) infected Sf21 cells using anti-IRE1 α antibody

Once the viral titer and time for expression were optimized, the cell lysates were collected for purification of the protein. We used the MBP tag on the IRE1 α -CD to aid in the purification. Filtered and clarified lysate was run through the MBPTrap column to obtain IRE1 α -CD protein. The protein was of >85% purity based on densitometric analysis of the bands seen in an SDS-PAGE gel. Once IRE1 α -CD is purified, it can be used for binding assays to determine binding partners for the protein [21]. **Figure 8** below shows the various

fractions from the purification process outlined in the manuscript. The addition of an MBP-tag makes for a very specific purification. The yield of the expressed protein obtained after purification differs by the plasmids used, by baculoviral stocks and by the type of protein being expressed. The final volume of Sf21 cells infected for scale-up can be adjusted based on the yield of protein required.

CD-IRE1 wild type

Figure 8: A GelCode Blue stained SDS-PAGE showing the various fractions from the purification procedure of IRE1-CD. FT- Flowthrough, W- Wash fractions, E- Elute fractions. The ladder is the Precision Plus blue ladder (Bio-Rad, cat# 1610373). The E2 fraction shows a pure protein band at ~100kDa as expected

Sf21 insect cells combined with the pFastBac baculoviral system make a very robust, optimizable system for expression of eukaryotic proteins. MBP-IRE1 α -CD was successfully expressed and purified from Sf21 cells. This protocol can be easily modified to express any mammalian protein in Sf21 insect cells by modifying the PCR primers shown in **Table 4** for the desired CDS. Long term expression of the protein can be achieved by making frozen stocks of baculovirus infected Sf21 cells. The MBP tag can be cleaved off using AcTEV protease if it interferes with downstream assays and the protein can be cleaned up using a Ni-NTA column. An AKTA-FPLC automated system can be used to aid in purification of higher volumes of cell lysate. If a secretion tag is used and the protein of interest is secreted in the media, a 5mL MBPTrap column can be used with the AKTA FPLC system to automate the purification process.

5. Summary

Further characterization of the expressed IRE1 α protein is required to establish its structure, phosphorylation status and *in vitro* XBP1 splicing activity conclusively. The phosphorylation status of the protein can be identified by various methods. Feldman et al., used mass spectrometry techniques to identify the phosphorylated sites on IRE1 α [22]. This technique in conjunction with a Phos-tag gel would lend more information on the ratio of phosphorylated to unphosphorylated species in the purified protein[23], [24]. Using the Phos-tag ligand developed by Fujifilm Wako-Chem, an SDS-PAGE gel can be used to separate phosphorylated proteins from unphosphorylated forms. The Phos-tag ligand binds to the phosphate group and slows down migration of the phosphorylated band. This leads to a

separation of the phosphorylated and unphosphorylated species into separate bands. To confirm that the band pattern is because of distinct phosphorylation, purified protein samples can be treated with λ - phosphatase enzyme with activity towards phosphorylated serine, threonine and tyrosine residues. On treatment and subsequent application to a Phos-tag SDS-PAGE gel, the slower migrating band should disappear. *In vitro* XBP1 splicing can be assayed with a hairpin-RNA cleavage assay or by a fluorescence-based assay with a FRET-paired oligonucleotide [18].

If the protein structure needs to be determined, circular dichroism or small-angle X-ray scattering techniques can be used. Circular dichroism is a very useful tool to determine secondary structure as well as native folding of expressed or fusion proteins. Specifically, secondary structure can be determined using far-UV spectra and protein folding characteristics can be determined by monitoring spectra at different temperatures or in the presence of different denaturing agents [25].

Author Contributions: Conceptualization, A.O. and C.C.; Methodology, A.O.; Validation, A.O., G.J. and C.C.; Writing—original draft preparation, A.O.; Writing—review and editing, A.O., G.J, C.C.; Funding and Supervision, C.C.

Funding: This research was funded by National Science Foundation, grant number CBET 1510895, CBET 1547518 and CBET 1802992.

Acknowledgments: The authors would like to thank Dr. Xiangshu Jin, Michigan State University for providing the Sf21 cell line for this work.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

- [1] P. T. Wingfield, "Overview of the Purification of Recombinant Proteins," *Curr. Protoc. Protein Sci.*, vol. 80, p. 6.1.1-6.1.35, 2016.
- [2] S. Ventura, "Sequence determinants of protein aggregation: Tools to increase protein solubility," *Microb. Cell Fact.*, vol. 4, no. 11, pp. 1–8, 2005.
- [3] U. Rinas and J. E. Bailey, "Protein compositional analysis of inclusion bodies produced in recombinant *Escherichia coli*," *Appl. Microbiol. Biotechnol.*, vol. 37, no. 5, pp. 609–614, 1992.
- [4] X. Shi and D. Jarvis, "Protein N-Glycosylation in the Baculovirus-Insect Cell System," *Curr. Drug Targets*, vol. 8, no. 10, pp. 1116–1125, 2007.
- [5] R. Chen, "Bacterial expression systems for recombinant protein production: *E. coli* and beyond," *Biotechnol. Adv.*, vol. 30, no. 5, pp. 1102–1107, 2012.
- [6] X. Gao, P. Yo, and T. K. Harris, "Improved yields for baculovirus-mediated expression of human His 6-PDK1 and His6-PKB β /Akt2 and characterization of phospho-specific isoforms for design of inhibitors that stabilize inactive conformations," *Protein Expr. Purif.*, vol. 43, no. 1, pp. 44–56, 2005.
- [7] S. Müller, T. Sandal, P. Kamp-Hansen, and H. Dalbøge, "Comparison of expression systems in the yeasts *Saccharomyces cerevisiae*, *Hansenula polymorpha*, *Kluyveromyces lactis*, *Schizosaccharomyces pombe* and *Yarrowia lipolytica*. Cloning of two novel promoters from *Yarrowia lipolytica*," *Yeast*, vol. 14, no. 14, pp. 1267–1283, 1998.
- [8] J. C. Gupta, M. Jaisani, G. Pandey, and K. J. Mukherjee, "Enhancing recombinant protein yields in *Escherichia coli* using the T7 system under the control of heat inducible λ P(L) promoter," *J. Biotechnol.*, vol. 68, no. 2–3, pp. 125–134, 1999.
- [9] Y. Huang, Y. Li, Y. G. Wang, X. Gu, Y. Wang, and B. F. Shen, "An efficient and targeted gene integration system for high-level antibody expression," *J. Immunol. Methods*, vol. 322, no. 1–2, pp. 28–39, 2007.
- [10] H. P. Sørensen and K. K. Mortensen, "Advanced genetic strategies for recombinant protein expression in *Escherichia coli*," *J. Biotechnol.*, vol. 115, no. 2, pp. 113–128, 2005.
- [11] G. L. Rosano and E. A. Ceccarelli, "Recombinant protein expression in *Escherichia coli*: Advances and challenges," *Front. Microbiol.*, vol. 5, no. APR, pp. 1–17, 2014.
- [12] A. Croset *et al.*, "Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells," *J. Biotechnol.*, vol. 161, no. 3, pp. 336–348, 2012.
- [13] G. P. Subedi, R. W. Johnson, H. A. Moniz, K. W. Moremen, and A. Barb, "High Yield Expression of Recombinant Human Proteins with the Transient Transfection of HEK293 Cells in Suspension," *J. Vis. Exp.*, vol. 106, p. e53568, 2015.
- [14] M. M. Van Oers, G. P. Pijlman, and J. M. Vlak, "Thirty years of baculovirus-insect cell protein expression: From dark horse to mainstream technology," *J. Gen. Virol.*, vol. 96, no. 1, pp. 6–23, 2015.
- [15] M. Merlin, E. Gecchele, S. Capaldi, M. Pezzotti, and L. Avesani, "Comparative evaluation of recombinant protein production in different biofactories: The green perspective," *Biomed Res. Int.*, vol. 2014, 2014.

- 522 [16] M. Schröder and R. J. Kaufman, "The Mammalian Unfolded Protein Response," *Annu.*
523 *Rev. Biochem.*, vol. 74, pp. 739–789, 2005.
- 524 [17] R. L. Wiseman *et al.*, "Flavonol activation defines an unanticipated ligand-binding site
525 in the kinase-RNase domain of IRE1.," *Mol. Cell*, vol. 38, no. 2, pp. 291–304, Apr.
526 2010.
- 527 [18] F. Prischi, P. R. Nowak, M. Carrara, and M. M. U. Ali, "Phosphoregulation of Ire1
528 RNase splicing activity," *Nat. Commun.*, vol. 5, pp. 1–10, 2014.
- 529 [19] B. Shrestha, C. Smee, and O. Gileadi, "Baculovirus Expression Vector System : An
530 Emerging Host for High-Throughput Eukaryotic Protein Expression," in *Methods in*
531 *molecular biology (Clifton, N.J.)*, vol. 439, pp. 269–289.
- 532 [20] X. Dong, P. Stothard, I. J. Forsythe, and D. S. Wishart, "PlasMapper: A web server
533 for drawing and auto-annotating plasmid maps," *Nucleic Acids Res.*, vol. 32, no. WEB
534 SERVER ISS., pp. 660–664, 2004.
- 535 [21] H. Cho *et al.*, "Molecular mechanism by which palmitate inhibits PKR
536 autophosphorylation," *Biochemistry*, vol. 50, no. 6, pp. 1110–1119, 2011.
- 537 [22] H. C. Feldman, M. Tong, L. Wang, R. Meza-acevedo, A. Theodore, I. Lebedev, ... D.
538 J. Maly, "Structural and Functional Analysis of the Allosteric Inhibition of IRE1 α with
539 ATP-Competitive Ligands," *ACS Chem Biol*, vol. 11, no. 8, pp. 2195–2205, 2016.
- 540 [23] L. Qi, L. Yang, and H. Chen, "Detecting and quantitating physiological endoplasmic
541 reticulum stress," *Methods in enzymology* (1st ed., Vol. 490). Elsevier Inc., 2011.
- 542 [24] R. Volmer, K. van der Ploeg, and D. Ron, "Membrane lipid saturation activates
543 endoplasmic reticulum unfolded protein response transducers through their
544 transmembrane domains," *Proceedings of the National Academy of Sciences*, vol. 110,
545 no. 12, pp. 4628–4633, 2013.
- 546 [25] N. J. Greenfield, "Using circular dichroism spectra to estimate protein secondary
547 structure," *Nat. Protocols*, vol. 1, no. 6, pp. 2876–2890, 2006.

548

Supplemental file

I. Preparation of competent *E. coli* DH10Bac cells

Materials needed:

- i. *E. coli* DH10Bac (streak from glycerol stock onto a Luria agar plate containing tetracycline/kanamycin/gentamycin, get isolated colonies and inoculate single colony) in LB broth containing tet/kan/gent grown at 37°C at 200 rpm.
- ii. Ice cold centrifuge tubes, P10, P200, P1000 tips, microcentrifuge tubes and cryovials
- iii. Refrigerated centrifuge
- iv. Dimethyl sulfoxide (DMSO)
- v. FSB buffer: (Sterile filter through a 0.22 µm filter and store at 4°C)

Components	Company	Cat. no	Final concentration
Potassium acetate pH 7.5	Sigma-Aldrich	P1190	10 mM
MnCl ₂	Sigma-Aldrich	M1787	45 mM
CaCl ₂	Sigma-Aldrich	C5670	10 mM
KCl	Sigma-Aldrich	P9541	100 mM
[Co (NH ₃) ₆]Cl ₃	Sigma-Aldrich	481521	3 mM
Glycerol	Sigma-Aldrich	G5516	10 %

Protocol:

- i. Grow *E. coli* DH10Bac cells overnight until the OD is between 0.3-0.6. The LB media should contain kanamycin and tetracycline at the working concentrations listed in Table 8 of the main text.
** It is very important not to overgrow the culture**
- ii. Cool the cells in wet ice for 10-20 minutes.
From now on the cells should remain always ice cold
- iii. Pellet the cells by centrifugation, 10 min at 2500 rpm, 4°C.
- iv. Resuspend the cells gently in 24 ml of ice-cold FSB.
- v. Incubate on wet ice for 10-15 minutes.
- vi. Pellet then cells again as above.
- vii. Resuspend the cells in 8 ml of cold FSB.
- viii. Add 280 µL DMSO.
- ix. Incubate for 5 minutes on wet ice.
- x. Add 280 µL DMSO.
- xi. Incubate for further 5 minutes on wet ice.
- xii. Aliquot the cells in 200-400 µL batches to sterile single-use cryovials.
- xiii. Store in -80°C.
Do not store in liquid nitrogen

582 **II. Preparation of glycerol stocks for *E. coli* DH10Bac cells with recombinant bacmid**

583 **Materials needed:**

- 584 i. Glycerol (Sigma-Aldrich, cat # G5516)
- 585 ii. Cryovials (Sigma-Aldrich, cat# 5000-0020)

586 **Protocol:**

- 587 i. Prepare a 60% glycerol solution in water. Filter sterilize using a 0.22 µm filter or
- 588 autoclave the solution at 121°C for 15 mins.
- 589 ii. Grow *E. coli* DH10Bac cells with recombinant bacmid in LB media for 14-16 hrs.
- 590 The LB media should contain kanamycin, gentamicin and tetracycline at the working
- 591 concentrations listed in **Table 8** of the main text.
- 592 iii. Add 750 µL of cells and 250 µL of the glycerol solution to a cryovial.
- 593 iv. Invert a few times to mix properly.
- 594 v. Store at -80°C.

595

596

597

598 **III. Preparation of recombinant bacmid from *E. coli* DH10Bac cells**

599 **Materials needed:**

- 600 i. PureLink HiPure Plasmid Miniprep kit (buffers R3, L7, N3) (ThermoFisher, cat#
- 601 K210002)
- 602 ii. 100% isopropanol

603 **Protocol:**

- 604 i. For recombinant bacmids, use 15–25 mL of an overnight *E. coli* DH10Bac with
- 605 recombinant bacmid grown in Luria Broth.
- 606 ii. Pellet the cells at $5000 \times g$ for 7 minutes to harvest the cells. Remove all medium and
- 607 wash with PBS if necessary.
- 608 iii. Add 0.4 mL Resuspension Buffer (R3) with RNase A to the cell pellet in the tube and
- 609 resuspend the cells. Gently shake the tube until the cell suspension is homogeneous.
- 610 iv. Add 0.4 mL Lysis Buffer (L7). Place the cap on the tube and ensure it is secure. Mix
- 611 gently by inverting the capped tube until the lysate mixture is thoroughly
- 612 homogenous. **Do not vortex.**
- 613 v. Incubate the lysate at room temperature for 5 minutes. **Do not exceed 5 minutes.**
- 614 vi. Add 0.4 mL Precipitation Buffer (N3) and mix immediately by inverting the tube
- 615 until the mixture is thoroughly homogeneous. **Do not vortex.** Centrifuge the lysate at
- 616 $>12000g$ for 10 mins at RT.
- 617 **Don't load onto the column provided with the kit. It decreases yield of bacmid and*
- 618 *does not increase the quality of bacmid obtained**
- 619 vii. Take the supernatant gently without disturbing the pellet Add 0.63mL ice cold
- 620 isopropanol to the supernatant. Mix well and incubate at RT for 15 mins.
- 621 **Alternatively, keep overnight at $-20^{\circ}C$ for precipitation**
- 622 viii. Centrifuge tube at $>12000g$ for 30 mins
- 623 ix. Air dry the pellet for 10 mins, then resuspend the purified bacmid DNA in 60 uL
- 624 water.
- 625 x. Solubilize bacmid DNA for 1 hr at $65^{\circ}C$ or $4^{\circ}C$ overnight.
- 626 ** $4^{\circ}C$ overnight is much better than $65^{\circ}C$ **
- 627 xi. Measure concentration of bacmid with Nanodrop.

628

629